User profiles for "author:Silvio Danese"

Silvio Danese

Ospedale San Raffaele
Verified email at hsr.it
Cited by 75762

Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management

F D'amico, DC Baumgart, S Danese… - Clinical …, 2020 - Elsevier
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19) pandemic is
a worldwide emergency. An increasing number of diarrhea cases is reported. Here we …

Crohn's disease

G Roda, S Chien Ng, PG Kotze, M Argollo… - Nature Reviews …, 2020 - nature.com
Crohn's disease is an inflammatory bowel disease that is characterized by chronic
inflammation of any part of the gastrointestinal tract, has a progressive and destructive …

Development of the Crohn's disease digestive damage score, the Lemann score

B Pariente, J Cosnes, S Danese… - Inflammatory bowel …, 2011 - academic.oup.com
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available
instruments measure disease activity at a specific point in time. An instrument to measure …

STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD …

D Turner, A Ricciuto, A Lewis, F D'amico, J Dhaliwal… - Gastroenterology, 2021 - Elsevier
Background The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE)
initiative of the International Organization for the Study of Inflammatory Bowel Diseases …

[HTML][HTML] Vedolizumab as induction and maintenance therapy for ulcerative colitis

BG Feagan, P Rutgeerts, BE Sands… - … England Journal of …, 2013 - Mass Medical Soc
Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized …

[HTML][HTML] Tofacitinib as induction and maintenance therapy for ulcerative colitis

WJ Sandborn, C Su, BE Sands… - … England Journal of …, 2017 - Mass Medical Soc
Background Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have
potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further …

Epithelial NEMO links innate immunity to chronic intestinal inflammation

A Nenci, C Becker, A Wullaert, R Gareus, G Van Loo… - Nature, 2007 - nature.com
Deregulation of intestinal immune responses seems to have a principal function in the
pathogenesis of inflammatory bowel disease,,,. The gut epithelium is critically involved in the …

[HTML][HTML] Ozanimod as induction and maintenance therapy for ulcerative colitis

WJ Sandborn, BG Feagan, G D'Haens… - … England Journal of …, 2021 - Mass Medical Soc
Background Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under
investigation for the treatment of inflammatory bowel disease. Methods We conducted a …

3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 2: surgical management and special situations

P Gionchetti, A Dignass, S Danese… - Journal of Crohn's …, 2017 - academic.oup.com
This paper is the second in a series of two publications relating to the European Crohn's and
Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management …

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis

R Panaccione, S Ghosh, S Middleton, JR Márquez… - Gastroenterology, 2014 - Elsevier
Background & Aims The comparative efficacy and safety of infliximab and azathioprine
therapy alone or in combination for ulcerative colitis (UC) have not been evaluated …